Eli Lilly and Company has announced the acquisition of California-based biotech company, Protomer Technologies.
List view / Grid view
Mergers & Acquisitions
Graeme Duncan, CEO at ADVANZ PHARMA, discusses how targeted strategic investment within the off-patent sector can add value and enhance choice for patients and healthcare professionals alike, while helping to drive and maintain innovation within the pharmaceutical industry.
The UK’s competition authority will assess whether AstraZeneca’s acquisition of Alexion will result in a “substantial lessening of competition”.
The UK’s National Security and Investment Bill: a new paradigm for investment, M&A and licensing for life sciences companies
Rebecca Le Flufy, Ross McNaughton and Adrian Toutoungi from Taylor Wessing LLP review the potential impacts of the UK’s National Security and Investment Bill on the life sciences industry and how it could influence future deals.
The Federal Trade Commission will work with international regulators to review the effects of pharma mergers and update approaches to analysing them.
Global mergers and acquisitions (M&A) activity last year was expected to decline from 2019 levels, mainly due to the COVID-19 pandemic and resulting uncertainty around the global economy, trade tensions between the US and China, and the presidential election in the US. However, James Baillieu from Bird & Bird reveals…
According to Jazz Pharmaceuticals, the combined company will be a leader in neuroscience, well positioned to maximise the value of its diversified portfolio.
Analysts say M&A deals continue to be a core driver of pharma/biopharma industry growth and that 2021 will likely be another year of high deal value.
Following approval by Emisphere shareholders, Novo Nordisk will acquire the company for a total of $1.8 billion.
A new report has highlighted that despite the pandemic, pharma M&A activity rose but deal value fell in the first half of 2020.
PerkinElmer will expand its automated life sciences discovery and applied genomics solutions with the acquisition.
Christoph Krähenbühl outlines five considerations for virtual pharmaceutical companies when launching a new drug product.